ライフサイエンスコーパス: booster

1 ailure based on its activity as a cyclic AMP booster.

2 s of anti-HBs measurements 30 days after the booster.

3 em frequencies before and after the 11-month booster.

4 -level therapists with a follow-up telephone booster.

5 included five weekly sessions and a 1-month booster.

6 n time since infant priming and receipt of a booster.

7 accine and in 100% of participants after the booster.

8 oster, or 3 placebo injections and a placebo booster.

9 riming schedule for infants, with a 12-month booster.

10 y series at ages 6, 10, and 14 weeks with no booster.

11 modification of protein N-termini with mass boosters.

12 city, often necessitating multiple doses and boosters.

13 -cell vaccines in a primary schedule without boosters.

14 e treated with 3 ILIT injections and an ILIT booster 1 year later, 3 ILIT injections and a placebo bo

15 g (11 core, 2 optional sessions; 2 telephone boosters; 2 home visits) provided specific strategies to

16 After the booster, 93.1%-100% of participants achieved MN titers o

17 , or 56-day intervals; eight groups received booster Ad26 or MVA vaccinations on Day 360.

18 prime followed by boosters administered by both i.n.

19 bset of 47 children who had received a JE-CV booster after an inactivated JE vaccine primary immuniza

20 pollen season was significantly lower in the booster AIT group (Delta=38.4%, P<.01).

21 Twice as many patients in the booster AIT group as in the control group reported havin

22 effects of a preseasonal, ultra-short-course booster AIT on clinical outcome parameters.

23 Booster AIT using tyrosine-absorbed allergoids containin

24 tients received one preseasonal short-course booster AIT using tyrosine-absorbed grass pollen allergo

25 The booster AIT was generally well tolerated, with only two

26 showed significant differences favouring the booster AIT.

27 HCWs) vaccinated as adults and response to a booster among those without protective levels of antibod

28 s with inadequate anti-HBs levels received a booster and 32 (94%) developed levels >12 mIU/mL within

29 We concluded that disulfiram can serve as a booster and adjuvant for anticancer immunotherapy.

30 HCWs with anti-HBs <12 mIU/mL were offered a booster and levels were measured 1, 7, and 21 days after

31 -dose, 719 (538-960) in one-dose plus 1-year booster, and 100 (50-201) in placebo recipients against

32 y room and had likely received a vaccination booster, and a total of 202 children showed higher vacci

33 men to induce immunity, along with an annual booster, and is composed of undefined culture supernatan

34 erization, reduce the dose of coadministered boosters, and discover compounds where deuterium is the

35 composition, multishot regimen, recommended boosters, and potential for adverse reactions.

36 After the booster, anti-HPV16/18 GMTs increased exponentially with

37 We aimed to compare the post-booster antibody response in UK infants given a reduced

38 % CI, 1.24-3.05) and for ritonavir used as a booster (aOR, 1.56; 95% CI, 1.11-2.20).

39 m, we report on infant immune responses to a booster aP vaccine dose in this randomized controlled cl

40 series of aP vaccines, was resolved with the booster aP vaccine dose.

41 ith SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection

42 rsion rates were significantly higher in the booster arm for the per-protocol population (53.8% vs 37

43 7.2) with a two-dose priming schedule plus a booster at 1 year).

44 2, 3, and 4 months after birth followed by a booster at 11 months and a 10-valent pneumococcal conjug

45 0 months and will be given (trial ongoing) a booster at 12 months (group 3), and 198 were given place

46 e at 0 months, or one dose at 0 months and a booster at 12 months) or placebo.

47 of WT JE strains at baseline, then after the booster at 28 days and 6 months in all subjects present

48 (6 + 14 group), with both groups receiving a booster at 9 months of age.

49 Receiving a booster at age 10-14 years decreased HBsAg seroprevalenc

50 ceived fIPV at 6 weeks and 14 weeks and fIPV booster at age 22 weeks.

51 group C received IPV at age 6 weeks and fIPV booster at age 22 weeks; and group D received fIPV at 6

52 group A received IPV at age 14 weeks and IPV booster at age 22 weeks; group B received IPV at age 14

53 roup B received IPV at age 14 weeks and fIPV booster at age 22 weeks; group C received IPV at age 6 w

54 was to investigate if a two-dose prime with booster at age 9 months compared with a three-dose prime

55 Use of a 2+1 PCV schedule with booster at age 9 months in a resource-poor setting impro

56 s, 4 months, and 12 months (2 primary [p] +1 booster [b] schedule).

57 phtheria, acellular pertussis (Tdap) vaccine booster between 2 consecutive pregnancies is investigate

58 Booster biocides have been widely applied to ships and o

59 tive to controlling contamination of fish by booster biocides, with low consumption of biodegradable

60 ed by postnatal nonmyeloablative same donor "booster" bone marrow (BM) transplants in murine models o

61 Based on SBA-3125, a booster campaign after 8 years would be required to sust

62 tudy is the first to demonstrate that NAD(+) boosters can also directly affect skeletal muscle mitoch

63 sisted of 4 weekly clinic appointments and 1 booster clinic at month 6, where multidisciplinary profe

64 ational interviewing with a 20- to 30-minute booster conducted by master's-level counselors.

65 , right ventricular free wall strain, and LA booster, conduit, and reservoir strains.

66 primary dose (day 1), one primary dose plus booster (days 1 and 365), or placebo.

67 Both the RRV and the final DNA boosters delivered a near-full-length SIVmac239 genome c

68 et, and few GCs arose following heterologous boosters, demonstrating that recall responses are confin

69 nsitional care including early follow-up and booster discharge instructions.

70 ine (PCV10) using three primary doses and no booster dose (3 + 0 schedule).

71 ubsequent cohorts, and one cohort received a booster dose after 1 year.

72 for protection after the primary series and booster dose and (2) serum IgG geometric mean concentrat

73 esponses were significantly increased upon a booster dose and remained at high levels even after thre

74 The duration of protection and need for a booster dose are unknown.

75 n 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule).

76 nt (TV005), and to evaluate the benefit of a booster dose at 6 months.

77 s (earlier than currently recommended) and a booster dose at 9-12 months of age.

78 ages 2 months, 4 months, and 6 months, and a booster dose at age 12 months.

79 every pregnancy was combined with a toddler booster dose at age 18 months; incidence was reduced to

80 also assessed the immunogenicity of an fIPV booster dose for an outbreak response.

81 Interestingly, a booster dose further enhances the immune responses, a fe

82 dose primary series of Hib vaccine without a booster dose has resulted in a significant and sustained

83 f conjugate Hib vaccine in infancy without a booster dose in Kenya.

84 -term immune responses induced after a JE-CV booster dose in toddlers were able to neutralize WT viru

85 Thus, a booster dose is likely to be unprofitable, considering t

86 trol persists, these findings suggest that a booster dose is not currently required in Kenya.

87 A 3-dose PCV13 regimen followed by a booster dose may be required to protect against pneumoco

88 We hypothesized that a booster dose might increase it.

89 3 years after primary vaccination, a single booster dose of 0.1 mL ID of HDCV was given to evaluate

90 We then assessed the effect of adding a booster dose of a modified vaccinia Ankara (MVA) strain,

91 enicity and reactogenicity of a heterologous booster dose of A/turkey/Turkey/1/2005(H5N1)-AS03B (AS03

92 nation schedules and the immunogenicity of a booster dose of both bivalent HPV vaccine (bHPV) or quad

93 n this interim report, we demonstrate that a booster dose of ChAdOx1 nCoV-19 is safe and better toler

94 a 2-dose schedule of bHPV or qHPV received a booster dose of either vaccine at month 61.

95 A booster dose of MenB-4C may be needed to maintain protec

96 lizing responses can be elicited by a single booster dose of protein following a long immunologic res

97 Those with levels <10 mIU/mL received 1 booster dose of recombinant hepatitis B vaccine 2-4 week

98 unteers to receive either BCG, followed by a booster dose of tetanus-diphtheria-pertussis inactivated

99 year-olds, similar to those expected after a booster dose of TT.

100 A booster dose of vaccine induced stronger antibody respon

101 activation, are substantially enhanced by a booster dose of vaccine.

102 individuals aged >/= 70 years who received a booster dose of ZV were compared to responses of 100 par

103 2012 using a 3-dose infant schedule with no booster dose or catch-up campaign.

104 oup was divided and allocated to a receive a booster dose or the other vaccine.

105 oup was divided and allocated to a receive a booster dose or the other vaccine.

106 chedule containing two primary doses and one booster dose provided 87.2% (95% confidence interval: 8.

107 Bs level >/=10 mIU/mL at 30 years and an 88% booster dose response, we estimate that >/=90% of partic

108 ccal serogroup B vaccines and the need for a booster dose to sustain individual protection against in

109 The immunogenicity of the booster dose was strongly associated with immunogenicity

110 for follow-up, 75 of 85 (88%) responded to a booster dose with an anti-HBs level >/=10 mIU/mL at 30 d

111 variations in PCV uptake (and receipt of the booster dose) might influence the effectiveness of PCVs

112 After a booster dose, all participants had neutralising activity

113 After the booster dose, at 10 months of age, there were no signifi

114 PCV10 vaccination, both before and after the booster dose, for all 4 shared serotypes except for sero

115 After the booster dose, protective antibody levels were achieved i

116 on of RTS,S/AS01 efficacy, with or without a booster dose, providing a valuable surrogate of effectiv

117 One month after the booster dose, significantly lower antibody titers were m

118 Following the booster dose, subjects exposed to the double-dose 2-visi

119 After an MMR vaccine booster dose, we noted a seroconversion of 74% of serone

120 rime" recipients for rapid protection with a booster dose, years later, of a vaccine then manufacture

121 ecific responses, persisting until after the booster dose.

122 orts from high-income countries giving a PCV booster dose.

123 ted for >/= 10 years and was enhanced by the booster dose.

124 ecific responses, persisting until after the booster dose.

125 e long-lived, rising to 30% (28-32%) after a booster dose.

126 er 2 years, subsets in each group received a booster dose.

127 ter RTS,S/AS01 vaccination with or without a booster dose.

128 ons following the primary vaccination and/or booster dose.

129 No safety concerns were identified with the booster dose.

130 body titer >0.5 IU/mL on day 7 following the booster dose.

131 Four participants did not receive a booster dose; 67 of 75 study vaccine recipients were fol

132 the VZV antibody response at 6 weeks in the booster-dose group, compared with the age-matched first-

133 her at baseline and after vaccination in the booster-dose group, compared with the first-dose group,

134 Booster doses are not needed.

135 lled by booster vaccination, suggesting Ad26 booster doses could be considered for individuals at ris

136 vaccine efficacy and the resulting need for booster doses create gaps in immunization coverage.

137 inistration in early versus later age and of booster doses for elderly individuals at an appropriate

138 In many countries, Hib vaccine booster doses have been implemented after infant immuniz

139 mly assigned to receive either 4 or 2 ID PEP booster doses of 0.1 mL PCEV during a single visit.

140 dy was still evident in reduced responses to booster doses of acellular pertussis, inactivated polio,

141 or placebo, and in 18 (32%) of 56 following booster doses of study product or placebo.

142 duct or placebo, and in 21 (38%) of 56 after booster doses of study product or placebo.

143 ins are sustained or attenuated, and whether booster doses of the intervention are needed to maintain

144 nding NYVAC-C-KC vectors (weeks 0 and 4) and booster doses with NYVAC-C-KC vectors plus the clade C H

145 gies such as different age-spacings, further booster doses, and cocooning.

146 serious adverse events were noted after the booster doses.

147 and remained at high levels even after three booster doses.

148 on schedules, and assessment of the need for booster doses.

149 antibody level (>0.5 IU/mL) 7 days after the booster doses.

150 The intervention group received booster education every visit by viewing a 15-minute edu

151 No booster effect was detected.

152 rity of infants after the primary series and booster, except for Haemophilus influenzae type b.

153 2 MOG-specific transgenic mice, and repeated boosters facilitated generation of activated CD44(high)

154 o employ it as a direct and universal signal booster for loop mediated isothermal reaction (LAMP).

155 tly higher in those who had received the MVA booster (geometric mean titer, 1750; P<0.001).

156 At month 13, post-booster, GMCs were equivalent between schedules for sero

157 o receive 1 dose (control group) or 2 doses (booster group) of the influenza vaccine 5 weeks apart.

158 seroprotection at 10 weeks was higher in the booster group: 54% vs 43.2% for A(H1N1)pdm; 56.9% vs 45.

159 brief intervention with attempted telephone booster had no effect on drug use in patients seen in sa

160 l children following infant (with or without booster) Hib vaccination.

161 es were available for analysis 1 month after booster immunisation versus 86 in group 2.

162 both Vaccine-NP and IAV groups following the booster immunisation.

163 Booster immunisations were given at weeks 16 and 18.

164 mmunization with G14D-CCV and at 3 d after a booster immunization as compared with control fish only

165 Also, in contrast with GBS-III, booster immunization of MenC-primed mice with isolated M

166 nd whether augmented IgG responses following booster immunization were also dependent on CD4(+) T cel

167 )ICOS(+) cTfh subset clonally expanded after booster immunization whose frequencies correlated with v

168 A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine a

169 ugmented PS-specific IgG response similar to booster immunization with intact MenC.

170 enhance PS-specific IgG responses following booster immunization with their encapsulated isogenic pa

171 various B cell populations, the response to booster immunization, and the generation of plasma cells

172 Activated MBCs were also induced by TT booster immunization, indicating that the expansion of t

173 accharide (PS)-specific IgG titers following booster immunization.

174 cells for augmented IgG responses following booster immunization.

175 ugmented PS-specific IgG responses following booster immunization.

176 d) were taken before and 28 days after PCV13 booster immunization.

177 CD8(+) T cell anamnestic response following booster immunization.

178 ne regimen used in RV144 have indicated that booster immunizations can increase serum anti-Env antibo

179 Two gp140 booster immunizations induced very high levels (~2 mg/ml

180 e they suggest that increasing the number of booster immunizations or delivering additional viral ant

181 This allows booster immunizations to rapidly expand CD8(+) central m

182 V1V2 trimeric scaffold immunogen followed by booster immunizations with a combination of DNA and prot

183 Three booster immunizations with a heterologous subtype C trim

184 again 1 week, 1 month, and 1 year after the booster in 250 healthy children aged 6-12 years in an op

185 ed by a modified vaccinia virus Ankara (MVA) booster, induced significant T cell-mediated, EBV-specif

186 hat received a primary infection with RSV, a booster infection with RSV ~2, ~6, or ~15 months later w

187 hat received a primary infection with RSV, a booster infection with RSV ~6 weeks later was completely

188 months later was highly restricted, whereas booster infections with the vectors had robust replicati

189 The booster injection 1 year later had no additional effect.

190 tered IM in 8 subjects/DL, with an identical booster injection 28 days later and 1-year follow-up.

191 A booster injection had no additional effect.

192 e additionally block-randomised to receive a booster injection on either day 28 or day 90 after the f

193 e antibody level >0.5 IU/mL 7 days after the booster injection.

194 e stable antibody titers induced by a single booster injection.

195 The second (booster) injection of MVA85A or placebo was given 6-12 m

196 Additional booster injections are required to augment the antibody

197 T cell expansion measured during subsequent booster injections over at least 100days.

198 immune factors, being the most potent immune booster known to science.

199 Two Apa-boosters markedly improved waning BCG-immunity and signi

200 We show that booster modified vaccinia virus Ankara immunization indu

201 y dose (n=398), one primary dose plus 1-year booster (n=1002), and placebo (n=199).

202 The SOSIP booster not only induced gp140-specific IgG, ADCC (antib

203 ecific memory B cells were measured before a booster of a Hib-serogroup C meningococcal (MenC) conjug

204 In this study, a 12-month booster of subtype C pox-protein vaccines restored immun

205 At one-month post-booster, only anti-FHA and anti-PRN antibodies were stil

206 Blood was collected before the 11-month booster or 7-9 days afterward.

207 year later, 3 ILIT injections and a placebo booster, or 3 placebo injections and a placebo booster.

208 in BCG-primed mice and investigated its BCG-booster potential.

209 uction of catch-up (2003) and routine (2006) booster programmes for young children.

210 (s)), LA conduit strain (epsilon(e)), and LA booster pump function active strain (epsilon(a)).

211 h analysis of atrial reservoir, conduit, and booster pump function trails in that regard, the gap is

212 ed with decreased LA reservoir, conduit, and booster pump functions.

213 ated with reduced LA conduit, reservoir, and booster pump LA function.

214 reservoir strain, LA conduit strain, and LA booster pump strain were quantified.

215 d radial strains; LA reservoir, conduit, and booster pump strains; and infarct size, edema, and micro

216 n with HIV molecules showed that CE+gag pDNA booster regimen further expanded the breadth of HIV CE r

217 Prime-booster regimens were given 28 days apart.

218 Following p27CE pDNA priming, two booster regimens, gag pDNA or codelivery of p27CE+gag pD

219 Higher baseline and post-Hib-MenC booster responses (anti-PRP IgG and memory B cells) were

220 enic and induce measurable IgG, PC, and Bmem booster responses at 11 months.

221 V induced multiple IgG subclasses and strong booster responses in all ages.

222 for nine of the 13 serotypes in PCV13, post-booster responses in infants primed with a single dose a

223 i, did not inhibit augmented PS-specific IgG booster responses of mice primed with heat-killed cells.

224 te that memory for augmented PS-specific IgG booster responses to Gram-negative and Gram-positive bac

225 However, post-booster responses, which are thought to drive herd immun

226 ith the antiretroviral (ARV) pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be com

227 Especially notable is the inability of booster schedules to alleviate resurgence when vaccines

228 e that the ultimate effectiveness of vaccine booster schedules will likely depend on correctly pinpoi

229 body titer >0.5 IU/mL on day 7 following the booster schedules.

230 r motorcyclists and bicyclists, car seat and booster seat use for child motor vehicle passengers, spe

231 iveness of CBP may be enhanced by additional booster sessions and concomitant treatment of parental d

232 drop-in classes versus home practice and PT booster sessions versus home practice.

233 Our results also suggest that an adolescence booster should be considered in individuals born to HBsA

234 compared to males, but was not the case with booster strain (14 +/- 7% vs. 12 +/- 6%, p = 0.45).

235 "leakiness." For scenarios I-IV, successful booster strategies were identified and varied considerab

236 In SOTR, a booster strategy 5 weeks after standard influenza vaccin

237 vector-based mucosal IL-4R antagonist/SOSIP booster strategy, which promotes cytotoxic mucosal CD4(+

238 ad significantly greater immunogenicity post-booster than those given the 2 + 1 schedule for serotype

239 nthracis in the wet season and can partially booster their immunity to B. anthracis.

240 the PWFA scheme very attractive as an energy booster to an electron-positron collider.

241 in vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses.

242 6 h each (18 h in total) on AIMS and a 1.5 h booster training session at the clinic (two to three nur

243 In countries with no pertussis booster until school age, continued monitoring of protec

244 ion (BMI) (n = 203), or BMI plus a telephone booster using personalized feedback or BMI + B (n = 193)

245 n motivational interviewing with a telephone booster using personalized feedback were most effective

246 Here, we introduce an in vitro booster vaccination approach that relies on antigen-depe

247 predictors of long-term immunity around the booster vaccination at 11 months of age.

248 V (Ad26) and MVA-BN-Filo (MVA) vaccines with booster vaccination at Day 360.

249 Effector T cells (TEFF) are a barrier to booster vaccination because they can rapidly kill Ag-bea

250 -adjuvanted vaccine followed by heterologous booster vaccination boosted immune responses to the homo

251 long-term protection against hepatitis B and booster vaccination does not appear to be necessary in H

252 Booster vaccination elicited anamnestic responses in all

253 However, the CE+gag pDNA booster vaccination elicited significantly broader CE ep

254 of immunity in many vaccinees suggests that booster vaccination is necessary to meet the 80% populat

255 Regular monitoring of seroresponse and booster vaccination might be warranted, especially in HI

256 Finally, an infection and heterologous booster vaccination model revealed no role for ZBTB32 in

257 tibodies at ~10 years postvaccination, and a booster vaccination should be considered for nonendemic

258 ens comprising CE pDNA prime and CE+gag pDNA booster vaccination significantly increased cytotoxic T

259 ission model, we searched for cost-effective booster vaccination strategies using a genetic algorithm

260 1 month after priming vaccine doses, before booster vaccination, and 1 month after booster vaccine d

261 Immunological memory was rapidly recalled by booster vaccination, suggesting Ad26 booster doses could

262 dverse events (AEs) following primary and/or booster vaccination.

263 types 4 and 19F after the primary series and booster vaccination.

264 ia for >/=30 years without requiring further booster vaccination.

265 nuclear cell samples after their primary and booster vaccination.

266 els were assessed for 6 months following the booster vaccination.

267 or repertoires following tetanus toxoid (TT) booster vaccination.

268 isted in all children 6 months following the booster vaccination.

269 ey/Turkey/1/2005(H5N1) 10 days following the booster vaccination.

270 of Tdap-vaccinated mothers after primary and booster vaccination.

271 concentrations after the primary series and booster vaccination.

272 of Tdap-vaccinated mothers after primary and booster vaccination.

273 it may no longer be necessary to administer booster vaccinations every 10 years and that the current

274 thylcellulose for eight courses, followed by booster vaccinations every 6 weeks.

275 Thus, booster vaccinations with agonistic costimulatory antibo

276 nti-HBs serum titers, the potential role for booster vaccinations, and antiviral prophylaxis prior to

277 many countries have nevertheless recommended booster vaccinations, the timing and number of which var

278 -neutralizing Ab responses should facilitate booster vaccinations.

279 ing durable responses may require additional booster vaccinations.

280 20) or half-dose (SD/LD D56; n = 32) ChAdOx1 booster vaccine 56 d following prime vaccination.

281 group received a two-dose schedule, with the booster vaccine administered 28 days after the first dos

282 efore booster vaccination, and 1 month after booster vaccine doses.

283 The rapid and robust response to a booster vaccine suggests a long-lasting amnestic respons

284 ntramuscular Modified Vaccinia Ankara (rMVA) booster vaccine, both expressing SIV antigens.

285 GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we evaluated the

286 iven one intramuscular dose (0.5 mL) of H5N1 booster vaccine.

287 different H5N1 antigen using low-dose Anhui (booster) vaccine.

288 antigen 85B [Ag85B]) (rLm30) as heterologous booster vaccines in animals primed with BCG.

289 Booster vaccines made in chloroplasts prevent global inf

290 rLmI/h30 vaccines were generally more potent booster vaccines than r30 with an adjuvant and a recombi

291 After 7.5 years, a vaccine booster was administered.

292 At 26 weeks, the fIPV booster was non-inferior to IPV (group B vs group A) for

293 uld have lost protective antibodies before a booster was proposed.

294 all seroconversion rate after a second dose (booster) was 93%.

295 , delivered as a three-dose series without a booster, was introduced into the childhood vaccination p

296 fter each vaccination until 1 year after the booster were assessed using an in-house standardised ELI

297 er the primary series, and 1 month after the booster were obtained from 220 preterm infants (74.3%).

298 in elevated and do not increase with vaccine boosters, whereas in whole-cell vaccine-primed children,

299 1 year later, after a booster with an inactivated H5N1 vaccine (part 2), 39 (9

300 ources, and an attempted 10-minute telephone booster within 2 weeks (n = 435) or enhanced care as usu